Evidence map›Paper›PMID 36692284›Full record

ArticleeLife2023

Beta human papillomavirus 8E6 promotes alternative end joining.

Changkun Hu, Taylor Bugbee, Rachel Palinski, Ibukun A Akinyemi, Michael T McIntosh, Thomas MacCarthy, Sumita Bhaduri-McIntosh, Nicholas Wallace

Open access · goldAbstract read
In one paragraph

Article in eLife, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Changkun HuBasic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, United States.ORCID 0000-0002-4407-7144
Taylor BugbeeDivision of Biology, Kansas State University, Manhattan, United States.
Rachel PalinskiVeterinary Diagnostic Laboratory, Kansas State University, Manhattan, United States.
Ibukun A AkinyemiChild Health Research Institute, Department of Pediatrics, University of Florida, Gainesville, United States.
Michael T McIntoshChild Health Research Institute, Department of Pediatrics, University of Florida, Gainesville, United States.
Thomas MacCarthyLaufer Center for Physical and Quantitative Biology, Stony Brook University, Stony Brook, United States.
Sumita Bhaduri-McIntoshChild Health Research Institute, Department of Pediatrics, University of Florida, Gainesville, United States.
Nicholas WallaceDivision of Biology, Kansas State University, Manhattan, United States.ORCID 0000-0002-3971-716X
Kansas State University · USUniversity of Florida · USCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZAStony Brook University · US

Funding

RADx-UP: Improving the Response of Local Urban and Rural Communities to Disparities in Covid-19 TestingUL1TR002366 · NCATS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Mario Castro, JAMES STEVEN LEEDER · 2017 to 2026
$44.3M
Sex-specific effects of obestity on Influenza A virus infection and immunityP20GM130448 · NIGMS · KANSAS STATE UNIVERSITY · PI WAITHAKA MWANGI · 2020 to 2026
$15.8M
Using PCORnet to Expand the DS-CONNECT Cohort Through Healthcare System Recruitment, Incorporating Electronic Health Records, and Assessing Self-DeterminationU54HD090216 · NICHD · UNIVERSITY OF KANSAS LAWRENCE · PI COLOMBO, JOHN A. · 2016 to 2020
$6.2M
Molecular Regulation of Cell Development and Differentiation Phase III COBREP30GM122731 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI LITTLE, CHARLES D. · 2017 to 2021
$5.6M
High Throughput Sequencing System for KUMC Genomics CoreS10OD021743 · OD · UNIVERSITY OF KANSAS MEDICAL CENTER · PI SMITH, PETER G · 2017 to 2017
$493k
HPV Oncogenes Dysregulate Translesion SynthesisR15CA242057 · NCI · KANSAS STATE UNIVERSITY · PI WALLACE, NICHOLAS A · 2020 to 2020
$454k
NCATS NIH HHS UL1 TR002366NCI NIH HHS R15 CA242057NICHD NIH HHS U54 HD090216NIGMS NIH HHS P20 GM130448NIGMS NIH HHS P20GM130448NIGMS NIH HHS P30 GM122731NIH HHS NCI R15 CA242057 01A1NIH HHS S10 OD021743
6 · The paper itself

Abstract

Double strand breaks (DSBs) are one of the most lethal DNA lesions in cells. The E6 protein of beta-human papillomavirus (HPV8 E6) impairs two critical DSB repair pathways: homologous recombination (HR) and non-homologous end joining (NHEJ). However, HPV8 E6 only delays DSB repair. How DSBs are repaired in cells with HPV8 E6 remains to be studied. We hypothesize that HPV8 E6 promotes a less commonly used DSB repair pathway, alternative end joining (Alt-EJ). Using CAS9-based Alt-EJ reporters, we show that HPV8 E6 promotes Alt-EJ. Further, using small molecule inhibitors, CRISPR/CAS9 gene knockout, and HPV8 E6 mutant, we find that HPV8 E6 promotes Alt-EJ by binding p300, an acetyltransferase that facilitates DSB repair by HR and NHEJ. At least some of this repair occurs through a subset of Alt-EJ known as polymerase theta dependent end joining. Finally, whole genome sequencing analysis showed HPV8 E6 caused an increased frequency of deletions bearing the microhomology signatures of Alt-EJ. This study fills the knowledge gap of how DSB is repaired in cells with HPV8 E6 and the mutagenic consequences of HPV8 E6 mediated p300 destabilization. Broadly, this study supports the hypothesis that beta-HPV promotes cancer formation by increasing genomic instability.

Indexed as

DNA Breaks, Double-StrandedHuman Papillomavirus VirusesDNA End-Joining RepairDNA RepairHomologous RecombinationHumansbeta-HPVcancer biologyDSB repairHRhumaninfectious diseasemicrobiologyMMEJNHEJP300

Identifiers

PMID36692284
PMCPMC9897725
OpenAlexW4317870995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.